By Daniella Parra HistoIndex will present advancements in AI-powered stain-free tissue imaging for NASH clinical trials at the EASL Congress 2023. “HistoIndex’s participation in the EASL Congress and the acceptance of our research partners’ 14 abstract submissions exemplify our unwavering...

By Daniella Parra Avertix Medical and AdventHealth Orlando have introduced the Guardian™ System, an FDA-approved implantable heart attack detection and warning system. “I believe the Guardian System introduces a significant advancement in cardiac care, potentially transforming how we detect heart...

By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) announced the presentation of three abstracts at the 2023 SLEEP Annual Meeting, demonstrating the effectiveness and safety of their Precision Oral Appliance Therapy (OAT) devices for treating Obstructive Sleep Apnea (OSA), the company...

By Daniella Parra Swiss life sciences company Lunaphore presented data on the capabilities of its COMET platform in the study of the immune status of the tumor microenvironment, the company said in a statement. The research focused on immune checkpoint biomarkers...

By Daniella Parra Octave announced new data at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023, supporting the company’s solution for multiple sclerosis. Researchers assayed 747 patient samples with Octave’s Multiple Sclerosis Disease Activity (MSDA) test, finding eight...

By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) announced a study that demonstrated that its oral treatment devices are an effective and safe alternative to CPAP for moderate and severe obstructive sleep apnea. The company presented its research findings at the...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) said it named Megan Yung as Chief Strategy Officer and General Counsel. Ms. Yung brings expertise from her previous roles at SQZ Biotechnologies and her background in intellectual property law, Eterna said...

By Exec Edge Editorial Staff ProSomnus, Inc. (NASDAQ: OSA), said revenue surged 55 percent in the first quarter from a year earlier. Revenue totaled $5.8 million, up from $3.7 million in the first quarter of 2022, it said in a...

  By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA) said it has acquired Exacis Biotherapeutics’ global immuno-oncology platform, which includes their pipeline of engineered cell therapy programs for hematologic and solid tumors. The acquisition gives Eterna an exclusive global license...

  By Healthcare Edge Editorial Staff Biopharma company Ocean Biomedical (NASDAQ: OCEA) reported positive findings published in peer-reviewed journal Cancer Research, bolstering evidence of the potential impact of its anti-Chi3L1 antibody in suppressing severe glioblastoma tumor growth. “This is a...